Therapeutics might be the only way out of this mess.
No:
A) ~half the therapeutic market is migraine, on which Allergan has patents. B) it’s going to take significant time to develop the Daxxy specific protocol on Spastic Limb, which is the majority of the remainder C) by having to lower their price in aesthetics, and, unlike Allergan, using the same price in therapeutics plus lasting longer per treatment, the total market will be much lower.
There isn’t that much near term (next few years) money for Revance in therapeutics.
News 
Market Data 
Discover 
